There is a newer version of the record available.

Published July 14, 2021 | Version 1.0.0
Dataset Open

Risk of bias assessments and support for judgement with ROB 2 tool for the Cochrane Review: Remdesivir for the treatment of COVID-19

Creators

  • 1. Department of Intensive Care Medicine, Medical Faculty, RWTH Aachen University, Aachen, Germany
  • 2. Department of Anaesthesiology and Intensive Care, University of Leipzig Medical Center, Leipzig, Germany
  • 3. Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
  • 4. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
  • 5. Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

Description

Risk of bias assessments and support for judgement with ROB 2 tool for the Cochrane Review: Remdesivir for the treatment of COVID-19.

Notes

This review is part of the CEOsys project funded by the Network of University Medicine (Nationales Forschungsnetzwerk der Universitätsmedizin (NUM)) by the Federal Ministry of Education and Research of Germany (Bundesministerium für Bildung und Forschung (BMBF)), grant number 01KX2021.

Files

Files (444.9 kB)